PDCD1 and neoplasm: Similarly, a pretreatment dormant tumor infiltrating lymphocytes signature characterized by elevated CD3, but low granzyme-B and low Ki-67, was associated with better disease control rate and longer PFS in NSCLC patients that were treated with ICI, likely due to cytolytic activation/proliferation of dormant T-cells by PD1/PD-L1 blockade [45].